Galderma to acquire Spirig

Lausanne, Switzerland - Pharmaceutical company Galderma is poised to acquire Spirig Pharma, a move that will boost its line of products for treating various dermatologic conditions.

Some of Spirig’s product line includes treatments for skin barrier function impairment, photodamage and actinic keratosis. Spirig is based in Egerkingen, Switzerland, and Galderma plans to use this location to serve as its headquarters for its Swiss market operations, Business Wire reports.

Galderma produces treatments for a variety of dermatologic conditions, such as onychomycosis, pigmentary disorders, rosacea, acne and others.

“We are delighted to join forces with Spirig Pharma,” Humberto C. Antunes, Galderma CEO, said in a statement. “Spirig has a holistic approach to protecting, treating, restoring and preventing dermatological conditions which is closely aligned to that of Galderma.”

The acquisition is expected to close early this year. Galderma’s global corporate headquarters will remain in Lausanne.